TCA
NKGNW

Taconic Capital Advisors’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Taconic Capital Advisors’s Portfolio NKGNW Stock Details NKGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-69,942
Closed -$6.99K – 85
2024
Q4 		$6.99K Hold
69,942
– – ﹤0.01% 64
2024
Q3 		$4.95K Hold
69,942
– – ﹤0.01% 74
2024
Q2 		$6.92K Sell
69,942
-58
-0.1% -$6 ﹤0.01% 79
2024
Q1 		$11.2K Hold
70,000
– – ﹤0.01% 75
2023
Q4 		$4.95K Hold
70,000
– – ﹤0.01% 119
2023
Q3 		$27.6K Hold
70,000
– – ﹤0.01% 95
2023
Q2 		$14K Hold
70,000
– – ﹤0.01% 170
2023
Q1 		$9.81K Hold
70,000
– – ﹤0.01% 252
2022
Q4 		$5.94K Hold
70,000
– – ﹤0.01% 452
2022
Q3 		$11K Hold
70,000
– – ﹤0.01% 574
2022
Q2 		$18K Hold
70,000
– – ﹤0.01% 597
2022
Q1 		$42K Hold
70,000
– – ﹤0.01% 591
2021
Q4 		$81K Hold
70,000
– – ﹤0.01% 475
2021
Q3 		$81K Buy
+70,000
New +$87.4K ﹤0.01% 406

Other funds holding NKGNW

RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Taconic Capital Advisors's NKGNW Position: Q1 2025 in Review

Taconic Capital Advisors sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q1 2025, closing a stake of 69,942 shares — an estimated $6.99K sold.

Taconic Capital Advisors first reported a position in NKGNW in Q3 2021 and held it in 14 quarters. The position peaked at $81K in Q4 2021. 3 funds tracked by Wall St. Rank hold NKGNW as of Q1 2025.

  • Taconic Capital Advisors reported no remaining NKGen Biotech, Inc. Warrants position as of Q1 2025 after selling out during the quarter.
  • Taconic Capital Advisors sold 69,942 NKGen Biotech, Inc. Warrants shares in Q1 2025, an estimated $6.99K.
  • Taconic Capital Advisors first reported a position in NKGen Biotech, Inc. Warrants in Q3 2021 and held it in 14 quarters.
  • Taconic Capital Advisors's NKGen Biotech, Inc. Warrants position peaked at $81K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q1 2025.

Based on Taconic Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.